- cafead Feb 03, 2021 at 11:02: PM
via A high-profile AL amyloidosis program once left for dead has gotten new life.
Prothena is pushing forward with its former lead candidate NEOD001, now called birtamimab, in a Phase III study despite the experimental drug’s crash and burn in a Phase IIb trial roughly three years ago. The study evaluated birtamimab in rare, second-line cases of the disease, and researchers also looked at the frontline setting in a Phase III that had been expected to fail.
article source
Prothena is pushing forward with its former lead candidate NEOD001, now called birtamimab, in a Phase III study despite the experimental drug’s crash and burn in a Phase IIb trial roughly three years ago. The study evaluated birtamimab in rare, second-line cases of the disease, and researchers also looked at the frontline setting in a Phase III that had been expected to fail.
article source